Karim Z, Yi-Tzu NF, Yoshida EM

Language: English
References: 0
Page: 4-6
PDF size: 56.92 Kb.

Text Extraction

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
Nelson DR, et al. Hepatitis C infection is the leading cause of end stage liver disease worldwide. Standard therapy with pegylated interferon and ribavirin have resulted in suboptimal responses, particularly for genotype 1. However, the advent of new direct-acting antiviral agents against HCV have resulted in dramatically improved rates of cure of the virus.